- Todd R. Golub, MD, Margaret A. Shipp, MD, and Bruce M. Spiegelman, PhD, of Dana-Farber Cancer Institute, have been elected to the Institute of Medicine (IOM), a nongovernmental organization that advises the nation on issues related to biomedical science, medicine, and health.
Tags: Appointments, Honors
- Daphne A. Haas-Kogan, MD, has been appointed chair of the Department of Radiation Oncology at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) effective July 1, 2015, and will be appointed professor at Harvard Medical School. She will also be the Endowed Professor of Radiation Oncology at Brigham and Women’s Health Care.
Tags: Appointments, Radiation
- The Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control (DCPC) has awarded a $1.75 million 5 year grant to the Program for Young Women with Breast Cancer at Dana-Farber Cancer Institute to increase the awareness of breast cancer among women and enhance the support services for those diagnosed and treated. The Program for Young Women with Breast Cancer at Dana-Farber was one of only seven organizations to be awarded this competitive grant.
Tags: BreastCancer, Grants
- Dana-Farber is part of a select group of healthcare facilities nationwide to be named Leaders in LGBT Healthcare Equality by the Human Rights Campaign Foundation.
- As more terminally ill patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A new study by Dana-Farber Cancer Institute researchers shows for one group of terminally ill cancer patients, that is not what is happening.
Tags: EndOfLife, OvarianCancer
- A new study by researchers at Dana-Farber Cancer Institute shows a half-day educational program can help women successfully deal with side effects of ovary removing surgery as a cancer prevention measure.
Tags: OvarianCancer, Genetics
- A new form of gene therapy for boys with X-linked severe combined immunodeficiency syndrome (SCID-X1) — "bubble boy" disease — appears to be both effective and safe, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and collaborating institutions report in the New England Journal of Medicine.
- Sequencing a patient's tumor before and after a clinical trial yielded information on why the tumor responded to and eventually resisted treatment, identifying mutations that may help guide the treatment of patients with cancers with similar mutations.
Tags: TranslationalResearch, HeadNeckCancers
- Carl Novina, MD, PhD, a researcher in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute, is one of 10 scientists chosen to receive a 2014 National Institutes of Health Pioneer Award, which funds bold and innovative research proposals to attack challenging biomedical problems.
- Dennie Jones, MD, has been named medical director of Dana-Farber Cancer Institute at St. Elizabeth's Medical Center.
Showing 31-40 of 564 items